Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland

Stephen McIlroy, Djamil Vahidassr, D.A. Savage, F. Lloyd, Christopher Patterson, J.T. Lawson, Peter Passmore

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

alpha 1-antichymotrypsin (AACT) is a serine protease inhibitor that has been associated with amyloid plaques in the brains of patients with Alzheimer's disease (AD). It has been reported that AACT serum levels are higher in AD patients than in age and sex matched controls. In addition, polymorphisms in the signal peptide and 5' of the AACT gene have been reported to increase the risk of developing AD, Serum AACT has also been suggested to be associated with cognitive decline in elderly subjects. Our objective was to investigate whether a relationship existed between serum AACT levels, AACT genotypes and risk for AD in a case control association study using 108 clinically well defined late onset AD cases and 108 age and sex matched controls from Northern Ireland. We also wished to determine whether higher serum AACT affected levels of cognition as had been previously reported. Serum AACT levels were found to bet significantly raised in cases compared to controls (t = 3.8, df = 209, p
Original languageEnglish
Pages (from-to)260-266
Number of pages7
JournalInternational Journal of Geriatric Psychiatry
Volume15
Issue number3
Publication statusPublished - 2000

Fingerprint Dive into the research topics of 'Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland'. Together they form a unique fingerprint.

Cite this